100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
212316-86-4Losartan EP Impurity L (Potassium Salt)
● In Stock
| Catalogue No.: | VE0020370 |
|---|---|
| CAS No.: | 212316-86-4 |
| Mol. Formula: | C44H43Cl2KN12O |
| Mol. Weight: | 865.91 g/mol |
Additional information on CAS 212316-86-4
Parent drug
LosartanIUPAC Name
[2-Butyl-1-[[2′-[1-[[2-butyl-4-chloro-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazol-5-yl]methyl]-1H-tetrazol-5-yl]biphenyl-4-yl]methyl]-4-chloro-1H-imidazol-5-yl]methanol Potassium SaltPharmacopoeial Synonyms
Losartan Related Compound DOther Synonyms
Losartan 1H-Dimer;N1-Losartanyl-losartan (Losartan Impurity) Potassium Salt;Losartan Impurity 16;1H-Imidazole-5-methanol, 2-butyl-1-[[2′-[1-[[2-butyl-4-chloro-1-[[2′-(1H-tetrazol-5-yl)[1, 1′-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]methyl]-1H-tetrazol-5-yl][1, 1′-biphenyl]-4-yl]methyl]-4-chloro-, monopotassium salt;1H-Imidazole-5-methanol, 2-butyl-1-[[2′-[1-[[2-butyl-4-chloro-1-[[2′-(2H-tetrazol-5-yl)[1, 1′-biphenyl]-4-yl]methyl]-1H-imidazol-5-yl]methyl]-1H-tetrazol-5-yl][1, 1′-biphenyl]-4-yl]methyl]-4-chloro-, potassium salt (1:1);Potassium 5-[4′-[[2-Butyl-4-chloro-5-[5-[4′-[[2-Butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl]methyl]biphenyl-2-yl]tetrazol-1-yl]methyl-1H-imidazol-1-yl]methyl]biphenyl-2-yl]tetrazolideDescription
Losartan EP Impurity L, also designated Losartan 1H-Dimer, is a structurally defined process-related dimeric impurity of the angiotensin II receptor antagonist losartan potassium. CAS 212316-86-4 corresponds to a chlorinated, nitrogen-rich species with molecular formula C44H43Cl2KN12O and molecular weight 865.91 g/mol. Its occurrence is typically associated with coupling or overreaction during synthesis of the biphenyl tetrazole intermediate or final API conversion, rather than simple oxidative degradation. Because of its extended heteroaromatic framework and low-level occurrence, characterization commonly relies on LC-MS/MS, high-resolution MS, and orthogonal RP-HPLC with photodiode array detection.Request a Quote
"*" indicates required fields
Other products related to Losartan impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
![Des[2’-(1H-tetrazol-5-yl)] 2-Cyanolosartan](https://veeprho.com/wp-content/uploads/2022/07/Losartan-Potassium-Related-Compound-B.png "Des[2’-(1H-tetrazol-5-yl)] 2-Cyanolosartan")
